Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry
Journal article published in 2021 by
Joel M. Kremer 
,
Clifton O. Bingham ,
Laura C. Cappelli ,
Jeffrey D. Greenberg,
Ann M. Madsen,
Jamie Geier,
Jose L. Rivas,
Alina M. Onofrei,
Christine J. Barr,
Dimitrios A. Pappas ,
Heather J. Litman,
Kimberly J. Dandreo,
Andrea B. Shapiro,
Carol A. Connell,
Arthur Kavanaugh
,
Clifton O. Bingham ,
Laura C. Cappelli ,
Jeffrey D. Greenberg,
Ann M. Madsen,
Jamie Geier,
Jose L. Rivas,
Alina M. Onofrei,
Christine J. Barr,
Dimitrios A. Pappas ,
Heather J. Litman,
Kimberly J. Dandreo,
Andrea B. Shapiro,
Carol A. Connell,
Arthur Kavanaugh
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 